Literature DB >> 6858898

Cardiovascular effects of breathing 95 percent oxygen in children with congenital heart disease.

R H Beekman, A P Rocchini, A Rosenthal.   

Abstract

The hemodynamic effects of breathing 95% oxygen were evaluated in 26 children with congenital heart disease. Aortic, pulmonary arterial, right atrial, and pulmonary arterial wedge pressure, aortic and pulmonary artery oxygen saturation, and blood gas, cardiac index, and heart rate were measured in room air and after each patient had breathed 95% oxygen for 10 (n = 26) and 20 (n = 5) minutes. Measurements were repeated with the patient again breathing room air for 10 (n = 11) and 20 (n = 6) minutes. After 10 minutes of 95% oxygen, arterial partial pressure of oxygen increased from 85 +/- 13 to 420 +/- 89 torr (p less than 0.001). Aortic mean pressure increased from 80 +/- 10 to 83 +/- 10 mm Hg (p less than 0.01), and systemic vascular resistance increased from 20 +/- 7 to 26 +/- 8 U (p less than 0.001). The cardiac index decreased by 21% from 3.96 +/- 0.94 to 3.12 +/- 0.74 liters/min/m2 (p less than 0.001) and the stroke index decreased by 11% (p less than 0.001). A 23% decrease in oxygen consumption (p less than 0.001) was observed, and oxygen transport decreased from 763 +/- 179 to 600 +/- 161 ml O2/min/m2 (p less than 0.001). Cardiac index, stroke index, and systemic vascular resistance did not return to normal until 20 minutes after cessation of oxygen breathing. To determine whether reflex bradycardia is responsible for these oxygen-induced hemodynamic changes, heart rate was kept constant by atrial pacing in a second group of 5 patients. In these children, significant decreases in cardiac index, stroke index, and oxygen consumption, and increases in systemic vascular resistance also occurred with 95% oxygen. Thus, in children with acyanotic congenital heart disease, hyperoxia increases aortic pressure and systemic vascular resistance and decreases cardiac index, stroke index, oxygen consumption, and oxygen transport.

Entities:  

Mesh:

Year:  1983        PMID: 6858898     DOI: 10.1016/0002-9149(83)90079-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Air ventilation during pulmonary artery banding operation.

Authors:  T Takahashi; Y Tosaki; I Sakuma; Y Shimada
Journal:  J Anesth       Date:  1993-04       Impact factor: 2.078

2.  Hyperoxia Reduces Oxygen Consumption in Children with Pulmonary Hypertension.

Authors:  Long Guo; Prashant Bobhate; Shine Kumar; Karunakar Vadlamudi; Tarek Kaddoura; Mohamed Elgendi; Paula Holinski; James Y Coe; Jennifer Rutledge; Ian Adatia
Journal:  Pediatr Cardiol       Date:  2017-03-18       Impact factor: 1.655

3.  Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children.

Authors:  M Wimmer; M Schlemmer
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

4.  Hemodynamic effects of nifedipine and oxygen in children with pulmonary hypertension.

Authors:  M Wimmer; M Schlemmer; F Ebner
Journal:  Cardiovasc Drugs Ther       Date:  1988-12       Impact factor: 3.727

5.  NF-κB involvement in hyperoxia-induced myocardial damage in newborn rat hearts.

Authors:  Susi Zara; Marianna De Colli; Monica Rapino; Valentina Di Valerio; Guya Diletta Marconi; Amelia Cataldi; Veronica Macchi; Raffaele De Caro; Andrea Porzionato
Journal:  Histochem Cell Biol       Date:  2013-04-09       Impact factor: 4.304

6.  Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces.

Authors:  Maria Jesus Del Cerro; Shahin Moledina; Sheila G Haworth; Dunbar Ivy; Maha Al Dabbagh; Hanaa Banjar; Gabriel Diaz; Alexandria Heath-Freudenthal; Ahmed Nasser Galal; Tilman Humpl; Snehal Kulkarni; Antonio Lopes; Ana Olga Mocumbi; G D Puri; Beyra Rossouw; S Harikrishnan; Anita Saxena; Patience Udo; Lina Caicedo; Omar Tamimi; Ian Adatia
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.